Syncom Formulations (India) Limited (SYNCOMF.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹20.66 (+3.15%) as of
Key statistics
- Market cap
- 19.42B
- P/E (TTM)
- 21.98
- EPS (TTM)
- 0.94
- Dividend yield
- 0.50%
- 52-week range
- 10.21 – 27.53
- Beta
- 0.83
- Revenue (TTM)
- 4.98B
- Profit margin
- 17.18%
- Volume
- 400.53k
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Indore, India
- Employees
- 902
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.